The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Open Payments Database
Sunshine Act
brand-name drugs
conflict of interest
industry
pharmaceutical industry
Journal
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
ISSN: 1097-6817
Titre abrégé: Otolaryngol Head Neck Surg
Pays: England
ID NLM: 8508176
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
25
9
2019
medline:
28
2
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
To associate pharmaceutical industry payments to brand-name prescriptions by otolaryngologists. Retrospective cross-sectional analysis. Open Payments Database and the Medicare Part D Participant User File 2013-2016. We identified otolaryngologists receiving nonresearch industry payments and prescribing to Medicare Part D recipients. Records were linked by physician name and state. The value of industry payments and the percentage of brand-name drugs prescribed per hospital referral region (HRR) were characterized as medians. Industry payments were correlated to the rate of brand-name prescription by Kendall's τ correlation. This was repeated at the individual physician level and stratified by payment type. In total, 8167 otolaryngologists received a median of $434 (interquartile range, $138-$1278) in industry compensation over 11 (3-26) payments. Brand-name drugs made up a median of 12.9% (8.6%-18-4%) of each physician's drug claims. The number (τ = 0.05, Industry financial transactions are associated with brand-name drug prescriptions in otolaryngologists, and these associations are stronger at the regional level than at the individual physician level. These correlations are of modest strength and should be interpreted cautiously by readers.
Identifiants
pubmed: 31547772
doi: 10.1177/0194599819852321
doi:
Substances chimiques
Prescription Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM